Estudios Clínicos en CER
= Estudios abiertos en busca de pacientes.
= Estudios en curso.
= Estudios finalizados.
= Material de Lectura / Información del estudio.
Estudios Clinicos Activos
Estudio | Año | Patología | Sponsor | Más |
---|
Estudios Finalizados
Estudio | Año | Patología | Sponsor | Más |
---|---|---|---|---|
To assess the efficacy and safety of LY2127399 in patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response to one or more TNF-α inhibitors | 2011 | AR | ELI LILLY | |
To assess the long-term safety and efficacy of LY2127399 in patients with rheumatoid arthritis (RA) | 2011 | AR | ELI LILLY | |
Multinational, multicenter, non-interventional study in patients with rheumatoid arthritis (RA) treated with tocilizumab | 2011 | AR | ROCHE | |
To evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) compared to etanercept (ETA) on the rate of cardiovascular events in patients with moderate to severe rheumatoid arthritis | 2012 | AR | ROCHE | |
Ptes treated with tocilizumab | 2012 | AR | SANOFI ADVENTIS | |
Record longitudinal results and cardiovascular comorbidities | 2012 | AR | CORRONA | |
International record of longitudinal results and cardiovascular comorbidities in patients with rheumatoid arthritis | 2012 | AR | ||
To assess the relative efficacy and tolerability of two doses Of MK 0663 / etoricoxib in patients with arthritis Rheumatoid | 2013 | AR | MERCK | |
To assess the efficacy and safety of baricitinib in patients with moderate to severe active rheumatoid arthritis who have failed to respond to methotrexate therapy | 2013 | AR | ELI LILLY | |
To assess the efficacy and safety of baricitinib (LY3009104) in patients with moderate to severe active rheumatoid arthritis who have received limited or no treatment with antirheumatic drug-modifying drugs | 2013 | AR | ELI LILLY |
Estudio | Año | Patología | Sponsor | Más |
---|---|---|---|---|
To assess the efficacy and safety of LY2127399 in patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response to one or more TNF-α inhibitors | 2011 | AR | ELI LILLY | |
To assess the long-term safety and efficacy of LY2127399 in patients with rheumatoid arthritis (RA) | 2011 | AR | ELI LILLY | |
Multinational, multicenter, non-interventional study in patients with rheumatoid arthritis (RA) treated with tocilizumab | 2011 | AR | ROCHE | |
To evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) compared to etanercept (ETA) on the rate of cardiovascular events in patients with moderate to severe rheumatoid arthritis | 2012 | AR | ROCHE | |
Ptes treated with tocilizumab | 2012 | AR | SANOFI ADVENTIS | |
Record longitudinal results and cardiovascular comorbidities | 2012 | AR | CORRONA | |
International record of longitudinal results and cardiovascular comorbidities in patients with rheumatoid arthritis | 2012 | AR | ||
To assess the relative efficacy and tolerability of two doses Of MK 0663 / etoricoxib in patients with arthritis Rheumatoid | 2013 | AR | MERCK | |
To assess the efficacy and safety of baricitinib in patients with moderate to severe active rheumatoid arthritis who have failed to respond to methotrexate therapy | 2013 | AR | ELI LILLY | |
To assess the efficacy and safety of baricitinib (LY3009104) in patients with moderate to severe active rheumatoid arthritis who have received limited or no treatment with antirheumatic drug-modifying drugs | 2013 | AR | ELI LILLY | |
To assess the efficacy and safety of baricitinib (LY3009104) in patients with moderate to severe active rheumatoid arthritis and insufficient response to conventional disease modifying antirheumatic drugs | 2013 | AR | ELI LILLY | |
Efficacy, pharmacokinetics and safety of BI 695500 against rituximab in patients with moderate to severe active rheumatoid arthritis: randomized, double-blind, parallel-group, multiple-dose and active comparator | 2013 | AR | BOHERINGER E | |
Multicenter, uncontrolled extension study evaluating the efficacy and safety of SAR153191 added to DMARD in patients with active rheumatoid arthritis (RA) | 2013 | AR | SANOFI ADVENTIS | |
To assess the safety and long-term efficacy of baricitinib in patients with rheumatoid arthritis | 2014 | AR | ELI LILLY | |
Alendronate controlled double-blind, multicenter, international, randomized trial to determine the efficacy and safety of AMG 785 in the Treatment of Postmenopausal Women with Osteoporosis. | 2014 | OTP | AMGEN | |
Phase 3 randomized, double-blind, placebo-controlled, active drug trial to evaluate the efficacy and safety of baricitinib in patients with moderate to severe active rheumatoid arthritis who have failed to respond adequately to methotrexate | 2014 | AR | ELI LILLY | |
Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of baricitinib (LY3009104) in patients with moderate to severe active rheumatoid arthritis and insufficient response to conventional disease-modifying antirheum | 2014 | AR | ELI LILLY | |
A Phase 3 randomized, double-blind, active-controlled study to evaluate the efficacy and safety of baricitinib (LY3009104) in patients with moderate to severe active rheumatoid arthritis who have received limited or no treatment with antirheumatic drugs | 2014 | AR | ELI LILLY | |
Phase 3 multicenter study to evaluate the safety and long-term efficacy of baricitinib in patients with rheumatoid arthritis | 2015 | AR | ELI LILLY | |
Multicenter, open-label, long-term follow-up study of the safety and efficacy of GLPG0634 in patients with moderate to severe active rheumatoid arthritis | 2015 | AR | GALAPAGOS | |
A randomized, double-blind, placebo-controlled, double-blind, phase IIb study administered for 24 weeks in combination with methotrexate in patients with moderate to severe active rheumatoid arthritis who had an inadequate response to methotrexate alone | 2015 | AR | GALAPAGOS | |
A randomized, double-blind, placebo-controlled, active-principle study of DS-5565 in patients with pain associated with fibromyalgia | 2016 | Fibromyalgia | DAICHI | |
A randomized, double-blind, placebo-controlled, active-principle study of DS-5565 in patients with pain associated with fibromyalgia | 2016 | AR | GEMA BIOTECH | |
Multicenter, double-blind, randomized study of denosumab versus zoledronic acid (Zometa®) for the treatment of bone metastases | 2006 | Advanced cancer (except breast and prostate cancer) or multiple myeloma | AMGEN INC | |
Open, randomized, multicenter study with two parallel branches to evaluate drug E7389 versus treatment of choice of physician | 2007 | Metastasic or locally recurrent breast cancer, previously treated with at least two and a maximum of 5 previous chemotherapeutic treatments, which included an anthracycline and a taxane | Eisai / ICON | |
A randomized, multicenter, open-label, phase III study of lapatinib, adjuvant trastuzumab, its sequence and combination | 2007 | Subjects suffering from her2 / erb2 positive primary breast cáncer | GlaxoSmithKline | |
An open-label extension study evaluating the safety and efficacy of Pazopanib | 2007 | Subjects with renal cell carcinoma previously incorporated into Protocol VEG105192 | Hoffmann – La Roche LTD | |
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind, AMG 706 Combined with Paclitaxel and Carboplatin | 2008 | Advanced Non Small Cell Lung Cancer | AMGEN INC | |
A multicenter, randomized, double-blind, Phase III study to investigate the efficacy and safety of oral BIBF 1120 plus standard treatment with pemetrexed Compared with placebo plus standard pemetrexed treatment | 2008 | Lung cancer to non-small cell stage IIIB / IV or recurrent after failure of first-line chemotherapy | Boehringer Ingelheim | |
A study evaluating the activity and safety of cetuximab as a maintenance treatment with 250 mg / m2 per week and 500 mg / m2 every two weeks after platinum-based chemotherapy in combination with cetuximab as a first-line treatment | 2008 | Subjects with advanced non-small cell lung cáncer | MERCK | |
A randomized, multicenter, open-label, phase III study of lapatinib, trastuzumab and its combination in neoadyuvancy plus paclitaxel | 2008 | Women with HER2 / ErB2 positive primary breast cáncer | GlaxoSmithKline | |
Phase III randomized, double-blind, placebo-controlled study to evaluate the efficacy of recMAGE-A3 + Antineoplastic Specific Immunotherapeutic Antineoplastic Antigen (AIAE) AS15 as adjuvant therapy | 2008 | Subjects with non-small cell lung cancer MAGE-A3 resectable positive | GlaxoSmithKline | |
Phase II randomized study of oral vinorelbine combination with capecitabine versus gemcitabine in combination with paclitaxel versus gemcitabine in combination with docetaxel as first-line chemotherapy | 2008 | Patients with metastatic breast cancer | PIERRE FABRE (ROVAFARM ARGENTINA S. A.) | |
Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Pertuzumab + Trastuzumab + Docetaxel versus placebo + Trastuzumab + Docetaxel | 2009 | HER2 positive metastatic breast cancer, previously untreated | Hoffmann – La Roche LTD | |
Open-label phase 2, randomized, active-controlled study of CS-7017 in combination with FOLFIRI | 2010 | Metastatic colorectal cancer that failed first line therapy | ICON | |
Randomized, Open, Multicenter, Phase 3, Epoetin Alfa plus Standard Support Therapy Versus Standard Support Therapy in Anemic Patients | 2010 | Metastatic Breast Cancer Receiving Standard Chemotherapy | Johnson & Jhonson | |
Randomized, double-blind, placebo-controlled study of PF-804 | 2010 | Patients with non-small cell lung cancer stage IIB / IV incurable following failure of standard therapy for advanced or metastatic disease | Worldwide Clinical Research S.A. (OIC) | |
Study open, phase II immunization with recMAGE-A3 + AS01B antitumor immunotherapy specific antigen | 2010 | Subjects with progressive and unresectable MAGE-A3 positive metastatic cutaneous melanoma | GlaxoSmithKline | |
Phase III clinical trial of vinflunine plus capecitabine versus capecitabine alone | 2010 | Patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are resistant to taxanes | PIERRE FABRE (ROVAFARM ARGENTINA S. A.) | |
A prospective, randomized, multicenter, open-label, phase III study of specific active immunotherapy with racotumomab added to the best Clinical support vs. The best clinical support | 2010 | Patients with advanced non-small cell lung cancer (cpcnp) | Research & Development RA S.A | |
Phase II trial of escalation of the dose until the appearance of exanthema of erlotinib (Tarceva®) plus gemcitabine | 2010 | Patients with metastatic pancreatic cancer | Hoffmann – La Roche LTD | |
A randomized, double-blind, placebo-controlled study evaluating the long-term safety and efficacy of darbepoetin alfa given at 500 μg once every 3 weeks in advanced-stage anemic subjects | 2011 | Non-small cell lung cancer under treatment with multiple cycles of chemotherapy | AMGEN INC | |
Randomized, multicenter, double-blind trial comparing the efficacy of ipilimumab added to paclitaxel and carboplatin versus placebo added to paclitaxel and carboplatin | 2011 | With stage IV / recurrent non-small cell lung cancer (NSCLC) | Eisai / ICON | |
A randomized, double-blind, placebo-controlled, multicenter, Phase 3 Denosumab as adjuvant treatment for women | 2011 | Early stage breast cancer with a high risk of recurrence | Quintiles/Amgen Inc | |
Phase 3, randomized, double-blind, placebo-controlled study of ARQ 197 plus Erlotinib versus Placebo plus Erlotinib | 2011 | Subjects with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC) treated previously | Daiichi Sankyo Pharma Development - ICON | |
A randomized, double-blind, multicenter, placebo-controlled study of lapatinib adjuvant | 2011 | Women with breast cancer with ErbB2 overexpression in early stage | GlaxoSmithKline | |
A randomized, open-label, phase III study of taxane-based chemotherapy with lapatinib or trastuzumab as first-line therapy | 2011 | Women with metastatic breast cancer her2 / neu positive | GlaxoSmithKline | |
Phase III study of gastric, esophageal or gastroesophageal adenocarcinoma | 2011 | Herb2 positivo, avanzado o metastásico, tratado con capecitabina más oxaliplatino, con o sin lapatinib | GlaxoSmithKline | |
A phase III study comparing the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus AI versus lapatinib plus AI as first-line therapy | 2011 | Postmenopausal women with HER2 positive, hormone receptor positive metastatic breast cancer (CMM) who have received trastuzumab and endocrine therapy in the neoadjuvant and / or adjuvant setting | GlaxoSmithKline | |
A randomized, double-blind, placebo-controlled Phase III study to evaluate the safety and efficacy of pazopanib as adjunctive therapy | 2011 | Subjects with localized or locally advanced renal cell carcinoma, after nephrectomy | GlaxoSmithKline | |
Everolimus phase III multicenter, randomized, double-blind, placebo-controlled study combined with Trastuzumab and Paclitaxel as first-line therapy | 2011 | Women with locally advanced or metastatic HER2 positive breast cancer | NOVARTIS | |
A randomized, double-blind, phase II multicentre, placebo-controlled study of everolimus given daily in combination with trastuzumab and vinorelbine in pretreated women | 2011 | Locally advanced or metastatic breast cancer with overexposure of HER2 / ne | NOVARTIS | |
Efficacy and safety of oral netupitant given in combination with palonosetron and dexamethasone compared to oral palonosetron and dexamethasone for the prevention of nausea and vomiting | 2011 | Cancer patients receiving moderately emetogenic chemotherapy | Helsinn Healthcare S.A | |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Farletuzumab's Efficacy and Safety (MORAb-003) Administered Once a Week in Combination with Carboplatin and Taxane | 2011 | Subjects with the First Recurrence of Platinum Sensitive Ovarian Cancer | PPD Argentina S.A. | |
Randomized, double-blind, phase 3 study of IMC 112B and best supportive care (MCS) versus placebo and MCS | 2011 | Treatment of gastric adenocarcinoma or metastatic gastroesophageal junction. After progression of disease with first line combination treatment containing platinum or fluoropyrimidin | ImClone LLC/Parexel International S.A | |
To evaluate the efficacy and safety of T-DM1 in combination with pertuzumab or T-DM1 in combination with pertuzumab placebo (blind for pertuzumab) compared to the combination of trastuzumab plus taxane as first-line treatment | 2011 | HER2 positive, progressive or recurrent, locally advanced metastatic breast cancer | Hoffmann – La Roche LTD | |
A randomized, double-blind, placebo-controlled, Phase III study of the effect of GTx-024 on loss of muscle mass | 2012 | In patients with non-small cell lung cancer who receive first-line chemotherapy based on platinum and a taxane | GTX | |
A Randomized Phase II, Open Label, Lapatinib-Capecitabine or Lapatinib / Vinorelbine or Lapatinib / Gemcitabine | 2012 | Metastatic breast cancer with Her2 / neu amplified with progression after taxane treatment | GAICO | |
Randomized, open-label study of BIBW 2992 in combination with vinorelbine versus trastuzumab in combination with vinorelbine | 2012 | Metastatic breast cancer with overexpression of HER2 that failed prior treatment with trastuzumab | PAREXEL International S.A / Boehringer Ingelheim | |
Pivotal study in patients with breast cancer to investigate the efficacy and safety of LA-EP2006 and Neulasta® | 2012 | Breast cáncer | Sandoz GmbH – i3 Latin America Argentina S.A | |
Single dose in parallel groups to evaluate the efficacy and safety of oral palonosetron 0.50 mg compared to palonosetron I.V. 0.25 mg administered with dexamethasone for the prevention of nausea and vomiting induced by chemotherapy | 2012 | Cancer patients receiving highly emetogenic cisplatin-based chemotherapy | Helsinn Healthcare S.A | |
A multicenter, randomized, double-blind, placebo-controlled study comparing the administration of chemotherapy plus trastuzumab plus placebo versus the administration of chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy | 2012 | Patients with HER2-positive operable primary breast cáncer | Hoffmann – La Roche LTD | |
Active comparator, parallel group, performed under internal blind conditions, to examine the efficacy and safety of a single dose of 150 mg Fosaprepitant Dimeglumine intravenously | 2012 | Prevention of chemotherapy-induced nausea and vomiting (CINV) related to moderately emetogenic chemotherapy | MERCK | |
Patient CA primary invasive HER2 positive breast, post definitive surgery. Period between surgery and random assignment at least 3 weeks post-surgery and no more than 7 weeks. Adjuvant chemo within the week of randomization | 2012 | Breast cáncer | Hoffmann – La Roche LTD | |
PegInterferon Lambda 1a with and without Daclatasvir compared to PegInterferon Alpha 2a, each combined with Ribavirin for the treatment of patients with Chronic Hepatitis C Genotypes 2 and 3 without pretreatmen | 2013 | Hepatitis | BMS | |
Pegylated interferon Lambda 1a in combination with Ribavirin and Daclatasvir for the treatment of chronic hepatitis C virus (HCV) genotypes 1, 2, 3 or 4 in HIV coinfected patients who have not received prior treatment | 2014 | Hepatitis | BMS | |
Phase III, randomized, double-blind, double-simulated, placebo-controlled, multicenter study to evaluate the efficacy (induction of remission) and safety of Etrolizumab compared to Adalimumab and placebo in patients with moderate to severe ulcerative coli | 2016 | Ulcerative colitis | ROCHE | |
Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Etrolizumab as an induction and maintenance treatment for patients with moderate to severe active Crohn's disease | 2016 | Crohn's Disease | ROCHE | |
Phase 3 multicenter, randomized, double-blind, placebo-controlled trial of oral RPC1063 as induction and maintenance therapy for moderate to severe ulcerative colitis | 2016 | Ulcerative colitis | RECEPTOS | |
To assess the safety and efficacy of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction | 2011 | Heart failure | NOVARTIS | |
Event-driven, canakinumab administered subcutaneously every 3 months in the prevention of recurrent cardiovascular events in a stable patient following an elevated hsCRP myocardial infarction | 2012 | Myocardial infarction | NOVARTIS | |
Fixed combinations of enofibrate / simvastatin 145/20 mg and enofibrato / simvastatin 145/40 mg versus monotherapies with the same drugs in subjects with dyslipidemia with a high risk of cardiovascular disease | 2012 | Cardiovascular disease | ABBOTT | |
Cardiovascular safety, and renal microvascular outcomes with linagliptin administered at a dose of 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk | 2014 | Diabetes mellitus type 2 with high vascular risk | Boehringer Ingelheim | |
Multicenter and international prospective registry of patients of both sexes with diagnosis of atrial fibrillation | 2014 | FA | Thrombosis Research Institute | |
A prospective, randomized, open blinded trial (PROBE) trial to evaluate DUAL antithrombotic therapy with dabigatran etexilate (110 mg and 150 mg bid) plus clopidogrel or ticagrelor compared to the triple therapy strategy with warfarin (INR 2.0 -3.0) plus | 2015 | FA | Boehringer Ingelheim | |
A randomized, controlled, 2 x 2 factorial clinical trial to evaluate the safety of Apixaban as compared to a vitamin K antagonist and aspirin compared to aspirin in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary int | 2016 | FA | BMS | |
Evaluar la seguridad y la eficacia del ácido zoledrónico en el tratamiento de la osteoporosis en mujeres posmenopáusicas que reciben calcio y vitamina D | 2001 | OTP | NOVARTIS | |
To assess the safety and efficacy of zoledronic acid in the treatment of osteoporosis in postmenopausal women receiving calcium and vitamin D | 2001 | OTP | NOVARTIS | |
Two different doses of BMS-188667 given IV in Ptes with Active RA while being treated with MTX | 2001 | AR | BRISTOL | |
To assess the safety and tolerability of BMS188667 administered IV in pts with active RA with or without concomitant diseases receiving antirheumatic drugs modifying current history of the disease | 2003 | AR | BRISTOL | |
To assess the efficacy and safety of BMS-188667 + MTX versus MTX alone with inadequate response to MTX | 2004 | AR | BRISTOL | |
Evaluate Abatacept or Infliximab in combination with Methotrexate for the control of disease activity in patients with Rheumatoid Arthritis who present inadequate clinical response to Methotrexate | 2005 | AR | BRISTOL | |
To assess the safety and efficacy of oral TAK-715 in the treatment of signs and symptoms of rheumatoid arthritis | 2005 | AR | PPD | |
To evaluate the safety and efficacy of Zoledronic Acid in the treatment of OTP in postmenopausal women receiving Calcium and Vit D | 2005 | OTP | NOVARTIS | |
Treatment with Tocilizumab (MRA) in pts who completed central studies | 2006 | AR | ROCHE | |
Determination of the dose of ATACICEPT, administered IV, ptes with RA and with insufficient response to tto with TNF antagonist | 2006 | AR | MERCK/SERONO | |
Dose Search to Evaluate the Effects of BA058 on the Treatment of Postmenopausal Women with OTP | 2006 | OTP | MDS | |
To evaluate the efficacy and safety of lyophilized CDP870, an engineered human PEG anti-TNF conjugate, as additional medication to methotrexate, in the treatment of signs and symptoms and prevention of structural damage | 2006 | AR | QUINTILES | |
To determine the effect of MRA as monotherapy, compared to a treatment regimen with MTX alone | 2006 | AR | ROCHE | |
Open Study of Diacerein (Arthroder) in the Treatment of Osteoarthritis | 2006 | AR | TRB | |
To assess the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who maintained methotrexate therapy | 2007 | AR | ROCHE | |
Atacicept in patients without previous treatment with anti-TNFα with moderate to severe active Rheumatoid Arthritis (RA) and with inadequate response to methotrexate | 2007 | AR | MERCK/SERONO | |
Effect on renal function of ibandronate, given as an i.v. bolus injection, as compared to an i.v. infusion, and alendronate | 2007 | OTP | ROCHE | |
Concept of SB-751689 in Postmenopausal Men and Women | 2007 | OTP | GLAXO | |
Multiple Doses and Pharmacokinetics / Pharmacodynamics of LY2189102 | 2007 | AR | ELI LLIY | |
OPTIMA protocol for the initiation of treatment with combination therapy of Metotrexate and Adalimumab in patients with RA | 2007 | AR | ABBOTT | |
To assess the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis with inadequate response to at least one anti-TNF therapy | 2007 | AR | ROCHE | |
To evaluate the safety and efficacy of ocrelizumab in combination Methotrexate (MTX) compared to MTX alone in patients with Untreated rheumatoid arthritis with methotrexate | 2007 | AR | ROCHE | |
Rituximab in combination with methotrexate (MTX), compared with methotrexate alone, in patients with active rheumatoid arthritis who have never received MTX | 2007 | AR | ROCHE | |
Two Subcutaneous Doses of IPP-201101 More Base Medications, Versus Placebo More Base Medications | 2007 | LES | IMMUPHARMA | |
Duloxetine versus Placebo in the Treatment of Chronic Low Back Pain | 2007 | LUMBALGIA | ELI LILLY | |
To evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of BG9924 administered in combination with methotrexate in subjects with active rheumatoid arthritis who have had an inadequate response to conventional therapy with DMARD | 2007 | AR | PPD ARGENTINA | |
To investigate the clinical efficacy of ofatumumab in subjects with active RA with inadequate response to treatment with MTX | 2008 | AR | I3 | |
Pts who have recently experienced an outbreak of systemic lupus erythematosus | 2008 | LES | MERCK | |
Combination of prolonged-release Tramadol hydrochloride and Meloxicam QD in the treatment of moderate to moderately severe pain | 2008 | OA | GLOBAL IQ | |
To assess the safety and efficacy of BG9924 administered in combination with Methotrexate in rheumatoid arthritis patients previously enrolled in the 104RA202 Study | 2008 | AR | PPD ARGENTINA | |
Pts who have not received prior biological treatment | 2009 | AR | ELI LLIY | |
Pts receiving concomitant MTX and an inadequate response to treatment with a TNFα inhibitor | 2009 | AR | OMNICARE | |
To assess the long-term efficacy and safety of 6-year and 9-year treatment with Zoledronic Acid in postmenopausal women with osteoporosis | 2009 | OTP | NOVARTIS | |
Tranilast with MTX concomitant compared to MTX | 2010 | AR | GLOBAL IQ | |
Subcutaneous administration (SC) of Tocilizumab in comparison to the administration (IV) of Tocilizumab, in combination with traditional anti-rheumatic disease modifying drugs (DMARD), in moderate to severe active RA | 2011 | AR | ROCHE | |
Inadequate response to a TNF-alpha antagonist | 2011 | AR | ASTRA ZENECA | |
Inadequate response to MTX | 2011 | AR | ASTRA ZENECA | |
Long-term extension of the previous OSKIRAS | 2011 | AR | ASTRA ZENECA | |
To assess the efficacy and safety of LY2127399 in patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response to treatment with methotrexate | 2011 | AR | ELI LILLY | |
AR Active who have presented an inadequate response to MTX monotherapy | 2011 | AR | KENDLE |